

**Mental Health Medication Advisory Committee  
Meeting Agenda, Open Session  
February 9, 2016, 2:00-4:00pm**

**Meeting Location:** HP Enterprise Services, Capital Room, 6511 SE Forbes Ave, Topeka, KS 66619

**Committee Members:** Susan Mosier, MD, MBA, FACS (Chair), Vishal Adma, MD, MS, CMQ, CPE, Holly Cobb, ARNP, Nicole Ellermeier, PharmD, Bradley Grinage, MD, Rebecca Klingler, MD, Charles Millhuff, DO, Karen Moeller, PharmD, BCPP, Taylor Porter, MD

**KDHE Staff:** Liane Larson, PharmD, MPH & Carole Arace

**MCO Staff:** Jonalan Smith, PharmD, FASCP, Sosunmolu Shoyinka, MD, Jennifer Murff, RPh, John Esslinger, MD, MMM, Joe Schlageck, MD, William Mack, MD

I. Call to Order

- A. Introductions
- B. Announcements

II. Old Business

- A. Review and Approval of December 9, 2015 Meeting Minutes
- B. Prior Authorization Criteria

1. Use of Multiple Concurrent Antipsychotics – Review proposed clinical criteria for adults and children prescribed multiple concurrent antipsychotic drugs.

- a. Prior Authorization Criteria
- b. Clinical Public Comment \*
- c. Committee Discussion

2. Use of Benzodiazepines and Buprenorphine Products – Review proposed clinical criteria for medication assisted treatment program patients prescribed benzodiazepines.

- a. Prior Authorization Criteria
- b. Clinical Public Comment \*
- c. Committee Discussion

### III. New Business

#### A. Prior Authorization Criteria

1. Stimulants and other ADD/ADHD Agents Dosing Limits – Review proposed daily dose limits for patients prescribed stimulants and other ADD/ADHD agents.

- a. Prior Authorization Criteria
- b. Clinical Public Comment \*
- c. Committee Discussion

2. Use of Stimulants and other ADD/ADHD Agents in Adults – Review proposed clinical criteria for adults prescribed stimulants and other ADD/ADHD agents.

- a. Prior Authorization Criteria
- b. Clinical Public Comment \*
- c. Committee Discussion

3. Use of Stimulants and other ADD/ADHD agents in children – Review proposed clinical criteria for children prescribed stimulants and other ADD/ADHD agents.

- a. Prior Authorization Criteria
- b. Clinical Public Comment \*
- c. Committee Discussion

### IV. Process Improvement Initiatives - For informational purposes only

#### A. Preferred Prescriber Status

1. Committee Discussion

#### B. DUR approved criteria timeline

1. Committee Discussion

### V. Open Public Comment\*

### VI. Adjourn

\* Clinical and open public comment requests and written testimony must be submitted 1 week prior to meeting to [llarson@kdheks.gov](mailto:llarson@kdheks.gov). If providing clinical comment, please indicate which agenda item you are requesting to comment on. Time limits during period of comment will be determined based on number of requests received.

**\*\*THIS AGENDA IS SUBJECT TO CHANGE\*\***